What medicine should I take after becoming resistant to Lorlatinib/lorlatinib?

Lorlatinib/Lorlatinib is a third-generation targeted drug, which is a treatment after resistance to second-generation targeted drugs. Lorlatinib in patients receiving treatment for the first time for ALKpositive non-small cell lung cancer, and in patients receiving crizotinib(second-generationALKtyrosine kinase inhibitor)ALKtyrosine kinase inhibitors.

All targeted drugs have a certain degree of efficiency, and the same is true for lorlatinib. A certain degree of drug resistance will develop after taking it for a long time. So what should you do if you become drug resistant to lorlatinib. Lorlatinib is a third-generation drug. Generally speaking, after resistance to third-generation drugs, patients should undergo genetic testing again according to the doctor's advice, or take first-generation drugs again. For some patients, taking first-generation drugs again has a certain efficiency.

Lorlatinib is a potent, brain-penetrating, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non-small cell lung cancer, including those with prior ALK Patients with tkifailure. Lorlatinib can pass the blood-brain barrier and has good efficacy in patients with brain metastases. Most of the adverse events of lorlatinib are mild and moderate, and are easily tolerated by patients. The most common adverse events are edema, peripheral neuropathy, cognitive effects, dyspnea, fatigue, weight gain, joint pain, emotional impact and diarrhea. The price per box of generic lorlatinib ranges from 3 to 5 thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.